体軸型脊椎関節炎におけるビメキズマブの有効性と安全性の比較: システマティックレビューとネットワークメタ解析
Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead598 Epub ahead of print
This systematic literature review and network meta-analysis provides evidence for bimekizumab being an efficacious option in the management of both b/tsDMARD-naïve and experienced patients across the axSpA spectrum, with similar safety and tolerability to existing treatments.
Here, Deodhar, et al. use a systematic literature review and network meta-analysis to compare the efficacy and safety of bimekizumab 160mg every 4 weeks, with b/tsDMARDs in nr-axSpA and AS.
Keywords:
